Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Langenbeck's Archives of Surgery
Erschienen in: Langenbeck's Archives of Surgery 3/2011

01.03.2011 | Review Article

Surgical treatment of gastrointestinal neuroendocrine tumors

verfasst von: Volker Fendrich, Detlef K. Bartsch

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are uncommon but clinically challenging and fascinating tumors. GEP-NETs present as either functional or as nonfunctional tumors. Functional tumors are commonly associated with a specific hormonal syndrome directly related to a hormone secreted by the tumor, like gastrinomas with a Zollinger–Ellison syndrome or carcinoid syndrome in patients with neuroendocrine tumors (NET) of the ileum. Nonfunctional tumors do not secrete a hormone resulting in a clinical syndrome.

Methods

The natural course of GEP-NETs is highly variable. Small, benign neoplasms such as 90% of all insulinomas or gastric endocrine tumors type 1 are readily curable by surgical resection; however, most other GEP-NETs have a much less favorable prognosis. Patients with completely resected tumors generally have a good prognosis, and an aggressive surgical approach in patients with advanced disease may also prolong survival.

Conclusions

This review focuses on the current standards of surgical treatment of gastric endocrine tumors, NETs of the pancreas (PNET) and NETs of the ileum. Although the evidence level is low in many instances due to the lack of randomized controlled trials, important treatment recommendations can be given.
Literatur
1.
Niederle MB, Hackl M, Kaserer K, Niederle B (2010) Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 17:909–918PubMedCrossRef
2.
Klöppel G, Scherübl H (2010) Neuroendocrine tumors of the stomach. Risk stratification and therapy. Pathologe 31:182–187PubMedCrossRef
3.
Akerström G, Hellman P (2007) Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:87–109PubMedCrossRef
4.
Borch K, Ahrén B, Ahlman H et al (2005) Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242:64–73PubMedCrossRef
5.
Ichikawa J, Tanabe S, Koizumi W et al (2003) Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 35:203–206PubMedCrossRef
6.
Delle Fave G, Capurso G, Milione M, Panzuto F (2005) Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol 19:659–673PubMedCrossRef
7.
Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P (2008) Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 15:337–342PubMedCrossRef
8.
Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H, Pauwels S, Kwekkeboom DJ, Rindi G, Frascati Consensus Conference Participants, European Neuroendocrine Tumor Society (2006) Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 84:158–164PubMedCrossRef
9.
Rindi G, Bordi C, Rappel S et al (1996) Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 20:168–172PubMedCrossRef
10.
Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135:1469–1492PubMedCrossRef
11.
Öberg K, Eriksson B (2005) Endocrine tumors of the pancreas. Best Pract Res Clin Gastroenterol 19:753–781PubMedCrossRef
12.
Komminoth P, Perren A, Oberg K, Rindi G, Kloppel G, Heitz PU (2004) (2004) Gastrinoma. In: DeLellis RA, Lloyd R, Heitz PU, Eng C (eds) Pathology and genetics of tumors of the endocrine organs. WHO Classification of Tumors. IARC Press, Lyon, pp 191–194
13.
Solcia E, Klöppel G, Sobin LH (2000) Histological typing of endocrine tumors. WHO International Histological Classification of Tumors, 2nd edn. Springer, Berlin, pp 56–70
14.
Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401PubMedCrossRef
15.
Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G, Wiedenmann B (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265PubMedCrossRef
16.
de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O'Toole D, Ferone D, Frascati Consensus Conference Participants, European Neuroendocrine Tumor Society (2006) Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 84:183–188PubMedCrossRef
17.
Danforth DNJ et al (1984) Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 96:1027–1036PubMed
18.
Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O'Connor JM, Pauwels S, Frascati Consensus Conference Participants, European Neuroendocrine Tumor Society (2006) Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84:173–182PubMedCrossRef
19.
Weber HC et al (1995) Determinants of metastatic rate and survival in patients with Zollinger–Ellison syndrome: a prospective long-term study. Gastroenterology 108:1637–1649PubMedCrossRef
20.
Yu F, Venzon DJ, Serrano J et al (1999) Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger–Ellison syndrome. J Clin Oncol 17:615–630PubMed
21.
Hoffmann KM, Furukawa M, Jensen RT (2005) Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 19:675–697PubMedCrossRef
22.
O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme MP, Caplin M, Jensen R, Eriksson B, Frascati Consensus Conference Participants, European Neuroendocrine Tumor Society (2006) Rare functioning pancreatic endocrine tumors. Neuroendocrinology 84:189–195PubMedCrossRef
23.
Nilsson O, Van Cutsem E, Delle Fave G, Yao JC, Pavel ME, McNicol AM, Sevilla Garcia MI, Knapp WH, Keleştimur F, Sauvanet A, Pauwels S, Kwekkeboom DJ, Caplin M, Frascati Consensus Conference Participants, European Neuroendocrine Tumor Society (2006) Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 84:212–215PubMedCrossRef
24.
Fendrich V, Langer P, Celik I et al (2006) An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 244:845–851, discussion 852–853PubMedCrossRef
25.
Bartsch DK, Fendrich V, Langer P et al (2005) Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242:757–764, discussion 764–766PubMedCrossRef
26.
Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, Gloor B, Martius F, Maecke H, Reubi JC (2009) Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 94:4398–4405PubMedCrossRef
27.
Fendrich V, Habbe N, Celik I et al (2007) Operative Therapie und Langzeitüberleben bei neuroendokrinen Pankreastumoren Erfahrungen bei 144 Patienten. Dtsch Med Wochenschr 2:195–200CrossRef
28.
Rothmund M, Angelini L, Brunt M et al (1990) Surgery for benign insulinoma: an international review. World J Surg 14:393–399PubMedCrossRef
29.
Hirshberg B et al (2002) Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg 194:761–764PubMedCrossRef
30.
Thompson NW (1998) Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Clin N Am 7:881–891
31.
Norton JA, Fraker DL, Alexander HR et al (1999) Surgery to cure the Zollinger–Ellison syndrome. N Engl J Med 341:635–644PubMedCrossRef
32.
Norton JA, Jensen RT (2004) Resolved and unresolved controversies in the surgical management of patients with Zollinger–Ellison syndrome. Ann Surg 240:757–773PubMedCrossRef
33.
Norton JA, Fraker DL, Alexander HR et al (2006) Surgery increases survival in patients with gastrinoma. Ann Surg 244:410–419PubMed
34.
Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J, Delle Fave GF, O'Toole D, Frascati Consensus Conference Participants (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87:47–62PubMedCrossRef
35.
Fendrich V, Langer P, Waldmann J et al (2007) The management of sporadic and MEN-1-gastrinomas. Br J Surg 94:1331–1341PubMedCrossRef
36.
Zogakis TG, Gibril F, Libutti SK et al (2003) Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg 238:42–48PubMedCrossRef
37.
Mignon M, Ruszniewski P, Podevin P et al (1993) Current approach to the management of a gastrinoma and insulinoma in adults with multiple endocrine neoplasia I. World J Surg 17:489–495PubMedCrossRef
38.
Tonelli F, Fratini G, Nesi G et al (2006) Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 244:61–70PubMedCrossRef
39.
Imamura M, Komoto I, Doi R et al (2005) New pancreas—preserving total duodenectomy technique. World J Surg 29:203–207PubMedCrossRef
40.
Hellman P, Andersson M, Rastad J et al (2000) Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg 24:1353–1360PubMedCrossRef
41.
Norton JA, Kivlen M, Li M et al (2003) Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138:859–866PubMedCrossRef
42.
Fendrich V, Waldmann J, Bartsch DK et al (2009) Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol 6:419–428PubMedCrossRef
43.
Kouvaraki MA, Solorzano CC, Shapiro SE et al (2005) Surgical treatment of non-functioning pancreatic islet cell tumors. J Surg Oncol 89:170–185PubMedCrossRef
44.
Bartsch DK, Schilling T, Ramaswamy A et al (2000) Management of nonfunctioning islet cell carcinomas. World J Surg 24:1418–1424PubMedCrossRef
45.
Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Steinmuller T, Oberg K, Scoazec JY, Frascati Consensus Conference Participants, European Neuroendocrine Tumor Society (2006) Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 84:196–211PubMedCrossRef
46.
Solorzano CC, Lee JE, Pisters PTW et al (2001) Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients. Surgery 130:1078–1085PubMedCrossRef
47.
Waldmann J, Fendrich V, Habbe N, Bartsch DK, Slater EP, Kann PH, Rothmund M, Langer P (2009) Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg 33:1208–1218PubMedCrossRef
48.
Skogseid B et al (1991) Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 73:281–287PubMedCrossRef
49.
Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B, European Neuroendocrine Tumour Society (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80:394–424PubMedCrossRef
50.
Kann PH, Balakina E, Ivan D et al (2006) Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 13:1195–1202PubMedCrossRef
51.
Thomas-Marques L, Murat A, Delemer B et al (2006) Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 101:266–273PubMedCrossRef
52.
Triponez F, Goudet P, Dosseh D et al (2006) Is surgery beneficial for MEN1 patients with small (< or = 2 cm), non-functioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 30:654–662, discussion 663–664PubMedCrossRef
53.
Gagner M (1996) Early experience with laparoscopic resections of islet cell tumors. Surgery 120:1051–1054PubMedCrossRef
54.
Langer P, Bartsch DK, Fendrich V, Kann PH, Rothmund M, Zielke A (2005) Minimal-invasive operative treatment of organic hyperinsulinism. Dtsch Med Wochenschr 130:508–513PubMedCrossRef
55.
Fernandez-Cruz L, Cesar-Borges G (2006) Laparoscopic strategies for resection of insulinomas. J Gastrointest Surg 10:752–760PubMedCrossRef
56.
Carrere N et al (2007) Spleen-preserving distal pancreatectomy with excision of splenic artery and vein: a case-matched comparison with conventional distal pancreatectomy with splenectomy. World J Surg 31:375–382PubMedCrossRef
57.
Akerström G, Hellman P, Hessman O (2005) Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 19:717–728CrossRef
58.
Akerström G, Hellman P, Hessman O (2005) Management of midgut carcinoids. J Surg Oncol 89:161–169PubMedCrossRef
59.
Habbe N, Fendrich V, Bartsch DK (2010) Solitary versus multiple carcinoid tumors of the ileum: a clinical analysis of 87 cases. Langenbecks Arch Surg 395:1179–1197CrossRef
60.
Gulec SA, Mountcastle TS, Frey D, Cundiff JD, Mathews E, Anthony L, O'Leary JP, Boudreaux JP (2002) Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg 68:667–671, discussion 671–672PubMed
61.
Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Frascati Consensus Conference Participants (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87:8–19PubMedCrossRef
62.
Arnold R, Rinke A, Klose KJ et al (2005) Octreotide versus octreotide plus interferon-ά in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 3:761–771PubMedCrossRef
63.
Ohrvall U, Eriksson B, Juhlin C, Karacagil S, Rastad J, Hellman P, Akerström G (2000) Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 24:1402–1408PubMedCrossRef
64.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663PubMedCrossRef
65.
Makridis C, Rastad J, Oberg K, Akerström G (1996) Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 20:900–906, discussion 907PubMedCrossRef
66.
Sarmiento JM et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37PubMedCrossRef
67.
Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–785PubMedCrossRef
68.
Dousset B, Saint-Marc O, Pitre J et al (1996) Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 20:908–914PubMedCrossRef
69.
Que FG, Nagorny DM, Batts KP et al (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169:36–42PubMedCrossRef
70.
Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA (1998) Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 187:88–192PubMedCrossRef
71.
Chamberlain RS, Canes D, Brown KT et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190:432–435PubMedCrossRef
72.
Nave H, Mossinger E, Feist H et al (2001) Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 129:170–175PubMedCrossRef
73.
Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Lévy P, Vilgrain V, Ruszniewski P, Belghiti J (2008) Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 247:659–665PubMedCrossRef
74.
Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13, 715 carcinoid tumours. Cancer 97:934–959PubMedCrossRef
75.
Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE (2009) Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 72:517–528PubMedCrossRef
76.
Pascher A, Klupp J, Neuhaus P (2005) Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 19:637–648PubMedCrossRef
77.
Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, Lang H, Klempnauer J, Manns MP, Boeker KH (2002) Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumours. Transplantation 73:386–394PubMedCrossRef
Metadaten
Titel
Surgical treatment of gastrointestinal neuroendocrine tumors
verfasst von
Volker Fendrich
Detlef K. Bartsch
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 3/2011
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-011-0741-7

Weitere Artikel der Ausgabe 3/2011

Langenbeck's Archives of Surgery 3/2011 Zur Ausgabe

Original Article

A modified fast-track program for pancreatic surgery: a prospective single-center experience

Review Article

The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors

Original Article

Impact of body image on patients’ attitude towards conventional, minimal invasive, and natural orifice surgery

Original Article

A fast intraoperative PTH point-of-care assay on the Philips handheld magnotech system

Original Article

Aggressive approach to acinar cell carcinoma of the pancreas: a single-institution experience and a literature review

Original Paper

The need for extended intensive care after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.